COVID-19’s first point-of-care test with CRISPR technology

Sherlock Bioscience And binx health announced that the two companies have entered into a partnership to develop the world’s first point-of-care diagnostic test COVID-19 (New Coronavirus Infection) (# If there is no character limit, add parentheses when first appearing Utilization of CRISPR technology.

Organization combines SHERLOCK with binx io diagnostic platform^TM CRISPR technology provides fast results. Their tests are likely to provide results at the consultation of one patient in many CLIA-exempted settings, such as clinics, doctor’s offices, life support centers, pharmacies and other consumer accessible facilities. Is designed to.

binx io is a molecular platform with FDA approval for testing chlamydia and gonorrhea and a unique detection method with the ability to detect infectious disease targets in body fluids. The platform consists of desktop-sized equipment and disposable cartridges with a multiplex capacity of up to 24 targets. After the patient sample is added to the cartridge and loaded into the instrument, the process is fully automated, producing on-screen “detected” or “undetected” results.

Jeff Luber, CEO of binx, said: health. In April, binx health first introduced the FDA-approved molecular diagnostic device for chlamydia and gonorrhea in both men and women, offering the same on-site diagnosis.

“Our proprietary platform leverages Sherlock’s CRISPR-based assays combined with binx’s electrochemical detection for rapid virus detection of SARX-CoV-2 without the need for additional equipment. Technology integration is designed to help physicians, clinicians, and other healthcare professionals at the forefront of the global COVID-19 pandemic decide on-the-spot care and control and prevent further infections ..

Rherul Dhanda, co-founder, president and CEO of Sherlock Biosciences, also stressed the importance of being able to make decisions in the field. “The reaction to provide a large number of tests, including Sherlock’s own test, increased access to important results during the pandemic. While there are personalized solutions to go to the hospital, pharmacy and others. Tests will also need to be accessible in the field to enable individuals to make positive decisions to improve their health and prevent potential spread to the community,” Dunder said. GEN..

Sherlock agrees with binx Health’s “Everywhere Care” strategy that relies on easy-to-use home-based solutions in precision clinics. Sherlock hopes that diagnostics will be available everywhere they are needed to serve as part of a solution to the COVID-19 pandemic.

Current SHERLOCK CRISPR SARS-CoV-2 The kit is Sherlock (Specific Sensitive Enzyme Reporter Unlock) A method of programming a CRISPR molecule to detect the presence of a specific SARS-CoV-2 gene signature in specimens collected by healthcare providers from patients suspected of having COVID-19. The SHERLOCK CRISPR SARS-CoV-2 Kit is intended for use in CLIA laboratories to assay nasal swabs, nasopharyngeal swabs, oropharyngeal swabs, or bronchoalveolar lavage (BAL) specimens. Once the signature is found, the CRISPR enzyme is activated and emits a detectable signal, giving results in about 1 hour. This kit is the first CRISPR-based diagnostic test to receive an EUA from the FDA Qualitative detection of nucleic acids from SARS-CoV-2.

Return to May, GEN Sherlock talked to Danda while building relationships with suppliers, manufacturers and partners. Daunder has expressed their hopes “for the best results for public health,” and the partnership seems to bear fruit.

Sherlock is also developing the INSPECTR home testing platform to create a device-free handheld test similar to a home pregnancy test for rapid detection of the SARS-CoV-2 virus.

Both companies will begin testing in the second half of 2020.